Earnings call: Vericel reports strong Q2 with record revenue growth By Investing.com
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 04 2024
0mins
Should l Buy VCEL?
Source: Investing.com
Strong Financial Performance: Vericel Corporation reported record revenue of nearly $53 million for Q2 2024, driven by growth in its MACI product and demand for NexoBrid, leading to an increase in gross margin and adjusted EBITDA. The company raised its profitability outlook and reaffirmed its revenue guidance for the year.
Future Growth Prospects: With upcoming product launches like MACI Arthro and anticipated FDA approval for a pediatric indication of NexoBrid, Vericel is well-positioned for continued revenue and profit growth in the competitive biotechnology market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VCEL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VCEL
Wall Street analysts forecast VCEL stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 33.460
Low
55.00
Averages
57.67
High
60.00
Current: 33.460
Low
55.00
Averages
57.67
High
60.00
About VCEL
Vericel Corporation is a provider of advanced therapies for sports medicine and severe burn care markets. It has a differentiated portfolio of cell therapy and specialty biologic products. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vericel Corporation Reports Record Q1 2026 Earnings with Increased Guidance
- Record Revenue: Vericel Corporation achieved total revenue exceeding $68 million in Q1 2026, reflecting a 30% year-over-year increase that significantly surpassed guidance, supporting profit growth and generating over $15 million in free cash flow.
- FDA Approval Milestone: The company received FDA approval for MACI commercial manufacturing at its new facility, which enhances manufacturing capacity and paves the way for potential MACI commercialization outside the U.S., likely driving further revenue growth.
- BARDA Contract Boost: Vericel secured a BARDA award valued at up to $197 million, with a base contract of $35 million that includes approximately $10 million for initial NexoBrid procurement over the next 12 months, providing strong support for future revenue growth.
- Guidance Increase: Following the outperformance in Q1, Vericel raised its total revenue guidance by $10 million for 2026, now expecting total revenue between $326 million and $336 million, reflecting the company's confidence in future growth prospects.
See More
Vericel Q1 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Highlights: Vericel reported a Q1 GAAP EPS of -$0.12, beating expectations by $0.03, indicating improvement in profitability despite still being in the red.
- Revenue Growth: The company achieved revenue of $68.4 million, a 30% year-over-year increase, surpassing market expectations by $4.78 million, reflecting strong demand for its products and driving overall performance.
- Adjusted EBITDA Surge: Non-GAAP adjusted EBITDA rose 195% to $9.6 million, representing 14% of revenue, showcasing significant progress in cost control and operational efficiency, which enhances confidence in future profitability.
- Strong Cash Flow Position: Operating cash flow stood at $16.4 million with free cash flow at $15.1 million, and the company holds approximately $211 million in cash and investments with no debt, indicating a robust financial position that provides ample funding for future expansion.
See More
Vericel Scheduled to Announce Q1 Earnings on May 7
- Earnings Announcement Date: Vericel (VCEL) is set to announce its Q1 2023 earnings on May 7 before market open, with consensus EPS estimate at -$0.16 and revenue forecast at $63.62 million, reflecting a 21% year-over-year growth.
- Earnings Estimate Variability: Over the past three months, EPS estimates have seen one upward revision and three downward adjustments, while revenue estimates have experienced three upward and three downward revisions, indicating mixed market sentiment regarding the company's profitability.
- Future Revenue Targets: Vericel aims to achieve revenue between $316 million and $326 million in 2026, driven by the expansion of its MACI sales force and the accelerating adoption of MACI arthroplasty, showcasing the company's confidence in future growth prospects.
- Significant Partnership Agreement: Vericel recently secured a $197 million BARDA deal, which will bolster its NexoBrid supply plans, further solidifying its market position in the biopharmaceutical sector.
See More
Cell Therapy Market Set to Nearly Double by 2035
- Market Growth Potential: The global cell therapy manufacturing market is projected to grow from $7.17 billion in 2026 to over $14 billion by 2035, with a compound annual growth rate of 15.2%, indicating strong demand and investment appeal in this sector.
- FDA Policy Advancement: In early 2026, the FDA formalized flexible manufacturing and quality control oversight, clearing the path for the transition from clinical validation to commercial products, thus accelerating industry growth and innovation.
- Avaí Bio's Progress: Avaí Bio, in partnership with Austrianova, has commenced the production of a Master Cell Bank (MCB) for α-Klotho protein, establishing a foundational infrastructure that ensures compliance with the highest quality standards for future cell therapy products.
- Technological Innovation and Market Demand: Avaí Bio's Cell-in-a-Box® encapsulation platform will utilize cells from the MCB to create a therapy that continuously produces Klotho protein, addressing the growing demand for anti-aging treatments and holding significant market potential.
See More
Vericel Secures $197M Contract with U.S. BARDA
- Significant Contract Value: Vericel has secured a 10-year contract worth up to $197 million with U.S. BARDA, including a $35 million base contract that allocates approximately $10 million for initial supply and early development over the next 12 months, indicating strong growth potential in the medical sector.
- Strategic Stockpile Expansion: Effective April 1, 2026, the contract allows for optional additional orders to expand the Strategic National Stockpile, highlighting Vericel's critical role in addressing public health emergencies and further solidifying its market position.
- Product Application Outlook: The early development focus on blast trauma applications is expected to drive demand for NexoBrid, enhancing the company's competitive edge in trauma treatment and laying the groundwork for future revenue growth.
- Revenue Forecast Increase: Vericel targets revenue between $316 million and $326 million in 2026, driven by the expansion of its MACI sales force and accelerating MACI arthro adoption, reflecting a proactive strategy in new product promotion and market penetration.
See More
Vericel Secures $197 Million BARDA Contract
- Significant Contract Value: Vericel Corporation has secured a ten-year contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) valued at up to $197 million, with a base contract amount of $35 million that includes approximately $10 million for initial NexoBrid procurement over the next 12 months.
- Strategic Importance: This contract encompasses not only the procurement of NexoBrid but also the establishment and maintenance of a Vendor Managed Inventory (VMI) system and the design and validation of a U.S. manufacturing facility, highlighting Vericel's critical role in addressing major public health emergencies.
- Market Expansion Potential: The contract includes options for additional NexoBrid procurement to expand the Strategic National Stockpile and funding for further clinical development for a potential blast trauma indication, indicating significant growth potential for the company in the market.
- Leadership Confidence: Vericel's CEO Nick Colangelo stated that this partnership will support U.S. national preparedness for severe burns and blast trauma injuries, further solidifying the clinical value and utilization of NexoBrid in the U.S. market.
See More
Vericel Corporation Reports Record Q1 2026 Earnings with Increased Guidance
- Record Revenue: Vericel Corporation achieved total revenue exceeding $68 million in Q1 2026, reflecting a 30% year-over-year increase that significantly surpassed guidance, supporting profit growth and generating over $15 million in free cash flow.
- FDA Approval Milestone: The company received FDA approval for MACI commercial manufacturing at its new facility, which enhances manufacturing capacity and paves the way for potential MACI commercialization outside the U.S., likely driving further revenue growth.
- BARDA Contract Boost: Vericel secured a BARDA award valued at up to $197 million, with a base contract of $35 million that includes approximately $10 million for initial NexoBrid procurement over the next 12 months, providing strong support for future revenue growth.
- Guidance Increase: Following the outperformance in Q1, Vericel raised its total revenue guidance by $10 million for 2026, now expecting total revenue between $326 million and $336 million, reflecting the company's confidence in future growth prospects.
See More
Vericel Q1 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Highlights: Vericel reported a Q1 GAAP EPS of -$0.12, beating expectations by $0.03, indicating improvement in profitability despite still being in the red.
- Revenue Growth: The company achieved revenue of $68.4 million, a 30% year-over-year increase, surpassing market expectations by $4.78 million, reflecting strong demand for its products and driving overall performance.
- Adjusted EBITDA Surge: Non-GAAP adjusted EBITDA rose 195% to $9.6 million, representing 14% of revenue, showcasing significant progress in cost control and operational efficiency, which enhances confidence in future profitability.
- Strong Cash Flow Position: Operating cash flow stood at $16.4 million with free cash flow at $15.1 million, and the company holds approximately $211 million in cash and investments with no debt, indicating a robust financial position that provides ample funding for future expansion.
See More
Vericel Scheduled to Announce Q1 Earnings on May 7
- Earnings Announcement Date: Vericel (VCEL) is set to announce its Q1 2023 earnings on May 7 before market open, with consensus EPS estimate at -$0.16 and revenue forecast at $63.62 million, reflecting a 21% year-over-year growth.
- Earnings Estimate Variability: Over the past three months, EPS estimates have seen one upward revision and three downward adjustments, while revenue estimates have experienced three upward and three downward revisions, indicating mixed market sentiment regarding the company's profitability.
- Future Revenue Targets: Vericel aims to achieve revenue between $316 million and $326 million in 2026, driven by the expansion of its MACI sales force and the accelerating adoption of MACI arthroplasty, showcasing the company's confidence in future growth prospects.
- Significant Partnership Agreement: Vericel recently secured a $197 million BARDA deal, which will bolster its NexoBrid supply plans, further solidifying its market position in the biopharmaceutical sector.
See More
Cell Therapy Market Set to Nearly Double by 2035
- Market Growth Potential: The global cell therapy manufacturing market is projected to grow from $7.17 billion in 2026 to over $14 billion by 2035, with a compound annual growth rate of 15.2%, indicating strong demand and investment appeal in this sector.
- FDA Policy Advancement: In early 2026, the FDA formalized flexible manufacturing and quality control oversight, clearing the path for the transition from clinical validation to commercial products, thus accelerating industry growth and innovation.
- Avaí Bio's Progress: Avaí Bio, in partnership with Austrianova, has commenced the production of a Master Cell Bank (MCB) for α-Klotho protein, establishing a foundational infrastructure that ensures compliance with the highest quality standards for future cell therapy products.
- Technological Innovation and Market Demand: Avaí Bio's Cell-in-a-Box® encapsulation platform will utilize cells from the MCB to create a therapy that continuously produces Klotho protein, addressing the growing demand for anti-aging treatments and holding significant market potential.
See More
Vericel Secures $197M Contract with U.S. BARDA
- Significant Contract Value: Vericel has secured a 10-year contract worth up to $197 million with U.S. BARDA, including a $35 million base contract that allocates approximately $10 million for initial supply and early development over the next 12 months, indicating strong growth potential in the medical sector.
- Strategic Stockpile Expansion: Effective April 1, 2026, the contract allows for optional additional orders to expand the Strategic National Stockpile, highlighting Vericel's critical role in addressing public health emergencies and further solidifying its market position.
- Product Application Outlook: The early development focus on blast trauma applications is expected to drive demand for NexoBrid, enhancing the company's competitive edge in trauma treatment and laying the groundwork for future revenue growth.
- Revenue Forecast Increase: Vericel targets revenue between $316 million and $326 million in 2026, driven by the expansion of its MACI sales force and accelerating MACI arthro adoption, reflecting a proactive strategy in new product promotion and market penetration.
See More
Vericel Secures $197 Million BARDA Contract
- Significant Contract Value: Vericel Corporation has secured a ten-year contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) valued at up to $197 million, with a base contract amount of $35 million that includes approximately $10 million for initial NexoBrid procurement over the next 12 months.
- Strategic Importance: This contract encompasses not only the procurement of NexoBrid but also the establishment and maintenance of a Vendor Managed Inventory (VMI) system and the design and validation of a U.S. manufacturing facility, highlighting Vericel's critical role in addressing major public health emergencies.
- Market Expansion Potential: The contract includes options for additional NexoBrid procurement to expand the Strategic National Stockpile and funding for further clinical development for a potential blast trauma indication, indicating significant growth potential for the company in the market.
- Leadership Confidence: Vericel's CEO Nick Colangelo stated that this partnership will support U.S. national preparedness for severe burns and blast trauma injuries, further solidifying the clinical value and utilization of NexoBrid in the U.S. market.
See More
